The Life Sciences Report
Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Metals ReportMore Experts
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
Sector Experts
Mara Goldstein
Mara Goldstein joined Cantor Fitzgerald & Co. from Thomson Reuters, where she served as director of research for Reuters Insight. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets. At Cantor, Goldstein covers the biotechnology sector. Goldstein also worked at Alex Brown & Sons and CS First Boston. She holds a bachelor's degree in economics from Purdue University.
Recent Interviews
The Life Sciences Report Watchlist 2013 (1/31/13) Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months.
Immunotherapies Attack Cancers and Grow Portfolios: Mara Goldstein (7/26/12) Sometimes valuations don't match the fundamentals of a stock, according to Cantor Fitzgerald & Co. Senior Biotechnology Analyst Mara Goldstein, who understands the science and its relationship to value. Goldstein recommends a handful of small-cap immunotherapy companies that were up 14–42% over the month of June; she also has one large-cap idea for more patient investors. In this exclusive interview with The Life Sciences Report, Goldstein makes a case for favorite companies that should continue making shareholders happy.
Recent Quotes
"GALE's NeuVax represents a new paradigm in treating patients." (5/10/13) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
"The NeuVax PRESENT trial will account for the largest component of GALE's future valuation." (1/31/13) Galena Biopharma Inc. - The Life Sciences Report Watchlist 2013 featuring Analyst Mara Goldstein More >
"GALE has an intriguing late-stage asset and is a story worth exploring." (12/10/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
"With an intriguing, late stage asset, GALE is worth exploring." (11/13/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
"GALE's modest valuation, late-stage assets and corporate profile are compelling." (8/15/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
"GALE is high-risk/high-reward with a relatively low valuation." (7/26/12) Galena Biopharma Inc. - The Life Sciences Report Interview with Mara Goldstein More >
"GALE is a story worth exploring, with milestone events forthcoming." (7/18/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
"We are initiating coverage of GALE with a Buy rating." (6/4/12) Galena Biopharma Inc. - Mara Goldstein, Cantor Fitzgerald More >
Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >